Protocol Ledger

NCT04035005 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Interventional Phase III clinical trial protocol NCT04035005 sponsored by Roche / Genentech in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-12 Enrollment: 1,013 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04035005
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,013 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04035005
Protocol FieldVerified Registry Value
NCT IdentifierNCT04035005
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment1,013 participants (ACTUAL)
Registered Start Date2019-08-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04035005
Hospital Research SiteLocationSite Profile
Georgetown University Medical CenterWashington D.C, DCOpen Hospital Dossier ->
University of Kansas Medical CenterKansas City, KSOpen Hospital Dossier ->
Austin HospitalHeidelberg, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI